An ongoing dialogue on HIV/AIDS, infectious diseases,
May 27th, 2010
HIV Treatment is Prevention!
The Lancet has just published a large prospective study demonstrating the protective effect of HIV treatment on the risk of viral transmission:
3381 couples were eligible for analysis … Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0·37 (95% CI 0·09—2·04) per 100 person-years in those who had initiated treatment and 2·24 (1·84—2·72) per 100 person-years in those who had not—a 92% reduction (adjusted incidence rate ratio 0·08, 95% CI 0·00—0·57, p=0·004).
A similar observation was made in an earlier study presented at CROI 2009, not yet published. Astoundingly, the rate of transmission in this Lancet paper could have been be zero if analyses were limited only to those with undetectable viral loads on treatment.
So here’s the bottom line: HIV treatment dramatically, hugely, ginormously reduces the risk of HIV transmission.
(My daughter several years ago predicted that ginormous would become a word. She was right.)
Yes, we can quibble with some of the details — the 2009 study did not include viral load measurements, this one in the Lancet was actually part of a study of HSV treatment hence the results are observational, protection from infection is not 100% — but is there any doubt that HIV treatment is currently our most effective way of preventing the spread of HIV?
Some will say that the definitive study on this issue is HPTN 052, which randomizes the HIV-infected member of a serodiscordant couple to go on treatment or to wait until the CD4 cell count drops below 250. The primary endpoint is the rate of infection among the seronegative partners.
But that study is likely to exclude those most likely to transmit HIV, since it’s limited to people with HIV who have no symptoms, a relatively high CD4 cell count, and hence on average a lower viral burden.
At this point, it seems a no-brainer to me. Treatment is prevention.
Categories: HIV, Infectious Diseases, Patient Care, Research
Tags: antiretroviral therapy, CROI, HIV, HPTN 052, Lancet, prevention
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “HIV Treatment is Prevention!”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country
- Sometimes You Just Need to Get Input from a Real Human Being
- Mystifying Abbreviations — Infectious Diseases Edition
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease
-
From the Blog — Most Recent Articles
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country January 27, 2026
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease January 21, 2026
FROM NEJM — Recent Infectious Disease Articles- Primary Measles Infection February 26, 2026A previously healthy man presented with a 5-day history of fever, nausea, and vomiting and a 2-day history of an itchy rash. Examination showed an exanthem consisting of minute macules and subtly elevated papules.
- Tecovirimat for the Treatment of Mpox February 26, 2026Mpox continues to spread in many communities. Tecovirimat has activity against orthopoxviruses in vitro. In a phase 3 trial involving patients with acute mpox, tecovirimat showed no evidence of clinical activity.
- Microbial Flora in War Wounds from the Ukrainian Front Line February 26, 2026Battlefield injuries are often contaminated with potentially infecting microbes. In this study, swabs obtained in the field after injury were profiled. Microbes and potential antimicrobial-resistance genes were characterized.
- AI-Enabled Precision-Education Systems — Transforming Lifelong Learning in Medicine February 26, 2026Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.
- From Efficacy to Access in Long-Acting HIV Therapy February 26, 2026Over the past three decades, advances in antiretroviral therapy (ART) have dramatically improved life expectancy, decreased frailty, and improved quality of life for persons with human immunodeficiency virus (HIV).1,2 These gains have accrued primarily among those who can reliably access health care and adhere to daily treatment. For...
- Primary Measles Infection February 26, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

This is revolutionary discovery that can extinguish the epidemic if we can provide cheap, instant rapid accurate self-administered ID of new HIV infection along with 24/7 cheap access to first line therapy.
Yep. Big ifs there, I acknowledge.
But something like this seems to be happening within certain communities — MSM in San Francisco and injection drug users in Vancouver. With a higher proportion on treatment, there’s a suggestion that incidence is declining.
In our clinic here in Nigeria, we have experienced 100% success rates in prevention of transmission in serodiscordant couples who want to get pregnant without access to high tech methods. We just advocate the couple to wait till infected partner has an undetectable viral load and they have unprotected sex or with the condom slit at the tip during the woman’s fertile period. If only we can assure cheap, properly monitored undisrupted treatment…
I appreciate your highlighting this important study. It is my sense that people who successfully access and sustain treatment with ART are different in many ways. I advocate for universal access to care and ART is part of that, but I wonder if the results will be sustained with all persons–I hope so, but I wonder.